Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE vs ACETAMINOPHEN AND CODEINE PHOSPHATE
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Butalbital is a barbiturate that potentiates GABA-A receptor activity, producing sedation; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, providing analgesic and antipyretic effects; caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy; codeine is an opioid agonist at mu-opioid receptors, producing analgesia via central mechanisms.
Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.
Relief of tension-type headache symptoms (FDA-approved),Treatment of migraine headache (off-label)
Mild to moderate pain,Pain accompanied by fever
1-2 capsules (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg) orally every 4 hours as needed, not to exceed 6 capsules per day.
One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.
Butalbital: 35-50 hours; Aspirin: 15-20 minutes (parent), salicylic acid: 2-3 hours at low doses, 15-30 hours at high doses; Caffeine: 3-7 hours; Codeine: 2.5-4 hours, morphine: 1.5-3.5 hours. Clinical context: Butalbital's long half-life contributes to prolonged sedation and risk of accumulation with repeated dosing.
Acetaminophen: 2–3 hours (prolonged in hepatic impairment). Codeine: 2.5–3.5 hours; metabolites: morphine 1.5–2.5 hours, codeine-6-glucuronide 3–4 hours. Clinical context: dosing interval every 4–6 hours.
Butalbital: hepatic via CYP2C19 and other CYP enzymes, partly excreted unchanged; aspirin: hydrolyzed to salicylate, conjugated in liver; caffeine: hepatic via CYP1A2 (major), CYP2E1, and CYP3A4; codeine: hepatic via CYP2D6 to morphine (active), CYP3A4 to norcodeine, and glucuronidation.
Acetaminophen: primarily glucuronidation and sulfation in liver; minor CYP450 (CYP2E1) to toxic NAPQI. Codeine: CYP2D6 to morphine; CYP3A4 to norcodeine; glucuronidation.
Codeine and its metabolites (morphine, codeine-6-glucuronide, norcodeine) are primarily excreted renally (>90%). Aspirin (acetylsalicylic acid) is hydrolyzed to salicylic acid, which is eliminated renally (75% as salicyluric acid, 10% as salicylic acid, 15% as other metabolites). Caffeine is largely metabolized in the liver and excreted renally (<3% unchanged). Butalbital is eliminated renally as metabolites and unchanged drug (about 60-70% as metabolites, 30-40% unchanged). Biliary/fecal elimination is minimal for all components.
Acetaminophen: renal elimination of conjugated metabolites (glucuronide 60%, sulfate 30%, cysteine/mercapturate <5%), less than 5% unchanged. Codeine: renal elimination of codeine (5–15%), morphine (5–10%), norcodeine (10–20%), and conjugates; 90% excreted in urine within 24 hours.
Butalbital: 20-30% (albumin); Aspirin: dose-dependent, 50-80% to albumin; Caffeine: 25-35% (albumin); Codeine: 20-25% (albumin).
Acetaminophen: 10–25% (albumin). Codeine: 7–25% (primarily albumin).
Butalbital: 0.5-0.6 L/kg; Aspirin: 0.15-0.2 L/kg; Caffeine: 0.6-1.0 L/kg; Codeine: 3-6 L/kg. Clinical meaning: High Vd for codeine indicates extensive tissue distribution.
Acetaminophen: 0.9 L/kg. Codeine: 3–6 L/kg (extensive tissue distribution).
Oral: Butalbital ~90%; Aspirin 80-100% (first-pass hydrolysis to salicylic acid); Caffeine ~100%; Codeine ~60-90% (first-pass metabolism to morphine).
Oral: acetaminophen 88% (variable first-pass); codeine 50–60% (first-pass metabolism to morphine, norcodeine, and conjugates).
Cr Cl 10-50 m L/min: Administer at 75% of usual dose every 6 hours; Cr Cl <10 m L/min: Administer at 50% of usual dose every 6 hours.
GFR 30-50 m L/min: administer every 6 hours; GFR 10-29 m L/min: administer every 8 hours; GFR <10 m L/min: administer every 12 hours; hemodialysis: not recommended.
Child-Pugh Class A: No adjustment; Child-Pugh Class B: Reduce dose by 50% and extend interval to every 6 hours; Child-Pugh Class C: Contraindicated.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50% and extend interval to every 8 hours; Child-Pugh C: contraindicated.
Not recommended for children under 12 years; for adolescents 12-18 years: 1 capsule orally every 4 hours as needed, not to exceed 4 capsules per day.
For children ≥12 years: acetaminophen 10-15 mg/kg/dose and codeine 0.5-1 mg/kg/dose orally every 4-6 hours; maximum acetaminophen 75 mg/kg/day, codeine 6 mg/kg/day. For children <12 years: not recommended due to codeine safety concerns.
Initiate at lowest effective dose; consider reducing dose by 50% and extending interval to every 6 hours due to increased risk of respiratory depression, renal impairment, and aspirin-induced gastrointestinal bleeding.
Start with lowest effective dose; acetaminophen component maximum 3 g/day; consider reduced codeine dose (e.g., 15 mg) due to increased sensitivity and risk of respiratory depression; extend dosing interval to every 6-8 hours.
Risk of medication overuse headache; codeine: risk of addiction, abuse, misuse, life-threatening respiratory depression, neonatal opioid withdrawal syndrome, and risks from concomitant use with benzodiazepines or other CNS depressants.
Risk of medication errors: confusion between milligram and milliliter doses, and between codeine and acetaminophen components. Contraindicated for postoperative pain management in children following tonsillectomy/adenoidectomy due to risk of respiratory depression and death.
Risk of Reye's syndrome with aspirin in children/viral illness; avoid exceeding recommended dosage due to rebound headache; GI bleeding risk with aspirin; opioid-induced respiratory depression, misuse, abuse, addiction; codeine use in children post-tonsillectomy/adenoidectomy; impaired alertness; risk of serotonin syndrome with serotonergic drugs; barbiturate dependence; caffeine withdrawal headache; hepatic/renal impairment; co-administration with alcohol or CNS depressants.
Hepatotoxicity (acetaminophen overdose); respiratory depression; drug dependence; ultra-rapid metabolizers of codeine (CYP2D6) leading to morphine toxicity; concomitant CNS depressants; use in pediatric patients; avoid alcohol.
Hypersensitivity to any component; pediatric patients with chickenpox or influenza-like illness (aspirin); significant respiratory depression; acute or severe bronchial asthma; GI obstruction; suspected surgical abdomen; breastfeeding (codeine); concurrent use with MAOIs or within 14 days; porphyria (barbiturates).
Hypersensitivity to acetaminophen or codeine; severe respiratory depression; acute or severe asthma; paralytic ileus; post-operative pain management in children after tonsillectomy/adenoidectomy; breastfeeding (in ultra-rapid metabolizers); concomitant MAOIs.
Avoid alcohol. High-fat meals may delay absorption. Avoid excessive caffeine intake from diet (coffee, tea, soda) to prevent additive stimulation. Maintain adequate hydration to reduce salicylate renal toxicity risk.
Avoid alcohol; high-fat meals may delay absorption but not clinically significant.
First trimester: Aspirin associated with increased risk of gastroschisis; codeine may increase risk of congenital malformations (orofacial clefts, cardiac defects) based on some studies. Second trimester: Risk of miscarriage with NSAIDs; codeine not clearly associated. Third trimester: Aspirin and codeine associated with premature closure of ductus arteriosus, oligohydramnios, neonatal hemorrhage, and respiratory depression; butalbital may cause neonatal withdrawal. Overall: Combination product has multiple teratogenic components; avoid in pregnancy unless benefit outweighs risk.
Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respiratory depression and neonatal withdrawal if used near term; may cause neural tube defects and other malformations with first-trimester exposure, but data are conflicting. Use lowest effective dose for shortest duration.
Aspirin and caffeine are excreted in breast milk; codeine is excreted in low amounts but may cause CNS depression in infants, especially in CYP2D6 ultrarapid metabolizers. Butalbital is excreted in low amounts. M/P ratio: Not established for this combination; codeine M/P ratio approximately 0.2-0.4. Use with caution; monitor infant for sedation, respiratory depression, poor feeding.
Acetaminophen is excreted into breast milk in low amounts (M/P ratio ~0.91-1.42) and is considered compatible with breastfeeding. Codeine is also excreted in breast milk; risk of infant opioid toxicity depends on maternal CYP2D6 phenotype. Ultra-rapid metabolizers may produce higher morphine levels. Use with caution, avoid in known CYP2D6 ultra-rapid metabolizers, and monitor infant for sedation and respiratory depression.
Due to increased plasma volume and renal clearance in pregnancy, lower serum concentrations may occur. However, no specific dosing adjustments are recommended due to lack of data; use lowest effective dose for shortest duration. Avoid in third trimester if possible.
No routine dose adjustment needed for acetaminophen. Codeine pharmacokinetics are altered in pregnancy: increased clearance and volume of distribution may require dose adjustment; however, due to variability in CYP2D6 metabolism, individualize dosing and monitor for efficacy and toxicity. Avoid codeine in pregnancy unless alternative analgesics are ineffective.
Combination analgesic with opioid and non-opioid components. Hepatotoxicity risk from aspirin in children and adolescents (Reye syndrome). Measure serum salicylate and acetaminophen levels in overdose, but codeine is a prodrug requiring CYP2D6 metabolism; poor metabolizers may have reduced efficacy while ultra-rapid metabolizers risk toxicity. Avoid in patients with G6PD deficiency (aspirin-induced hemolysis). Caffeine may potentiate analgesia but also cause CNS stimulation and dependence. Prescribe with caution in elderly due to fall risk.
For acute pain, limit codeine to 3 days; avoid in children under 12 due to CYP2D6 ultra-rapid metabolizer risk of fatal respiratory depression; monitor for constipation; assess liver function for acetaminophen hepatotoxicity; use with caution in renal impairment.
This medication contains codeine, which can be habit-forming; use only as prescribed.,Do not take with other products containing acetaminophen, aspirin, or caffeine.,Avoid alcohol; may increase risk of liver damage and sedation.,Stop use and seek medical attention if you experience ringing in ears, severe nausea/vomiting, or signs of Reye syndrome (children).,Do not drive or operate machinery until you know how this drug affects you.,Keep out of reach of children; accidental overdose may be fatal.
Take exactly as prescribed; do not exceed 4000 mg acetaminophen per day.,Avoid alcohol while taking this medication.,Do not use with other acetaminophen-containing products.,May cause dizziness or drowsiness; avoid driving until you know how you react.,Common side effects include constipation, nausea, and drowsiness.,Seek emergency if signs of allergic reaction or difficulty breathing occur.
"Concurrent use of diphenhydramine and butalbital results in additive central nervous system (CNS) depression due to their overlapping sedative-hypnotic properties. Diphenhydramine, a first-generation antihistamine, antagonizes histamine H1 receptors and crosses the blood-brain barrier, while butalbital, a barbiturate, enhances GABA-A receptor activity. This synergism can lead to excessive sedation, impaired cognitive and motor function, respiratory depression, and increased risk of accidental injury or overdose, particularly in elderly patients or those with hepatic impairment."
"Agomelatine, a melatonergic antidepressant, combined with butalbital, a barbiturate and central nervous system (CNS) depressant, leads to additive CNS depression. This interaction increases the risk of excessive sedation, respiratory depression, impaired psychomotor function, and potential overdose. Concurrent use may also alter hepatic metabolism via cytochrome P450 induction, reducing agomelatine efficacy and increasing butalbital toxicity."
"Amobarbital and Butalbital are both barbiturates that act as central nervous system (CNS) depressants. When co-administered, they exhibit additive CNS depression, leading to synergistic sedative and hypnotic effects, which can result in excessive sedation, respiratory depression, coma, or death. The combination significantly increases the risk of severe adverse outcomes, particularly in patients with compromised respiratory function or those taking other CNS depressants."
"Pirenzepine, a selective M1 muscarinic antagonist, reduces gastrointestinal motility and secretions, while codeine, an opioid agonist, also decreases gastrointestinal motility via mu-opioid receptors. Concurrent use leads to additive anticholinergic and opioid effects, resulting in enhanced risk of severe constipation, paralytic ileus, and central nervous system depression. Clinically, patients may experience exacerbated sedation, respiratory depression, and urinary retention."
"Ropinirole, a non-ergoline dopamine agonist used in Parkinson's disease and restless legs syndrome, may reduce the analgesic efficacy of codeine. This is likely due to pharmacodynamic antagonism at central dopamine and opioid receptors, as well as potential pharmacokinetic interactions that decrease the conversion of codeine to its active metabolite morphine via CYP2D6 inhibition by ropinirole. The resultant blunted opioid response can lead to inadequate pain control, necessitating dose adjustment or alternative therapy."
"Vemurafenib induces CYP3A4, significantly reducing the plasma concentrations of codeine, which is metabolized via CYP3A4 to its active metabolite morphine. This may diminish codeine's analgesic efficacy, potentially leading to inadequate pain control. Additionally, reduced formation of morphine may lower the risk of opioid-related adverse effects."
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE vs ACETAMINOPHEN AND CODEINE PHOSPHATE, answered by our medical review team.
BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is a Opioid Agonist that works by Butalbital is a barbiturate that potentiates GABA-A receptor activity, producing sedation; aspirin inhibits cyclooxygenase (COX-1 and COX-2), reducing prostaglandin synthesis, providing analgesic and antipyretic effects; caffeine is a non-selective adenosine receptor antagonist, enhancing analgesic efficacy; codeine is an opioid agonist at mu-opioid receptors, producing analgesia via central mechanisms.. ACETAMINOPHEN AND CODEINE PHOSPHATE is a Opioid Agonist that works by Acetaminophen: centrally acting analgesic and antipyretic, possibly via inhibition of cyclooxygenase (COX) and modulation of cannabinoid receptors. Codeine: prodrug converted to morphine; mu-opioid receptor agonist.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE and ACETAMINOPHEN AND CODEINE PHOSPHATE depend on the specific clinical indication. These are both Opioid Agonist agents and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is: 1-2 capsules (each containing butalbital 50 mg, aspirin 325 mg, caffeine 40 mg, and codeine phosphate 30 mg) orally every 4 hours as needed, not to exceed 6 capsules per day.. The standard adult dose of ACETAMINOPHEN AND CODEINE PHOSPHATE is: One or two tablets (acetaminophen 300 mg/codeine 30 mg per tablet) orally every 4-6 hours as needed for pain; maximum 12 tablets daily.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
A moderate-severity drug interaction has been identified when combining BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE and ACETAMINOPHEN AND CODEINE PHOSPHATE. The combination of codeine and butalbital results in additive central nervous system (CNS) depression due to their independent mechanisms of action. Codeine, an opioid agonist, binds to mu-opioid receptors in the brain and spinal cord, while butalbital, a barbiturate, enhances gamma-aminobutyric acid (GABA) activity at GABA-A receptors. Concurrent use increases the risk of profound sedation, respiratory depression, coma, and death, particularly in patients with compromised respiratory function or those taking other CNS depressants. Consult your prescriber before combining these medications.
The maternal-fetal safety profiles differ. BUTALBITAL, ASPIRIN, CAFFEINE, AND CODEINE PHOSPHATE is classified as Category D/X. First trimester: Aspirin associated with increased risk of gastroschisis; codeine may increase risk of congenital malformations (orofacial clefts, cardiac defects) based on some st. ACETAMINOPHEN AND CODEINE PHOSPHATE is classified as Category D/X. Acetaminophen is considered low risk in all trimesters at therapeutic doses; chronic high doses may be associated with adverse outcomes. Codeine is associated with risk of respirat. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.